PT - JOURNAL ARTICLE AU - Jane M Tiller AU - Nicole E Cousens AU - Rajneesh Kaur AU - Simone Rowley AU - Yi-An Ko AU - Sakshi Mahale AU - Agnes Bankier AU - Bettina Meiser AU - Kristine Barlow-Stewart AU - Leslie Burnett AU - Chris Jacobs AU - Paul James AU - Alison Trainer AU - Suzanne Neil AU - Ian G Campbell AU - Lesley Andrews AU - Martin Delatycki TI - Population-based <em>BRCA1/2</em> testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study AID - 10.1136/jmedgenet-2022-108519 DP - 2023 Mar 01 TA - Journal of Medical Genetics PG - 265--273 VI - 60 IP - 3 4099 - http://jmg.bmj.com/content/60/3/265.short 4100 - http://jmg.bmj.com/content/60/3/265.full SO - J Med Genet2023 Mar 01; 60 AB - Background Ashkenazi Jewish (AJ) people have a higher incidence of BRCA1/2 pathogenic variants (PVs) than unselected populations. Three BRCA-Jewish founder mutations (B-JFMs) comprise &gt;90% of BRCA1/2 PVs in AJ people. Personal/family cancer history-based testing misses ≥50% of people with B-JFM.Methods We compared two population-based B-JFM screening programmes in Australia—using (1) an online tool (Sydney) and (2) in-person group sessions (Melbourne).Results Of 2167 Jewish people tested (Sydney n=594; Melbourne n=1573), 1.3% (n=28) have a B-JFM, only 2 of whom had a significant cancer family history (Manchester score ≥12). Pretest anxiety scores were normal (mean 9.9±3.5 (6–24)), with no significant post-result change (9.5±3.3). Decisional regret (mean 7.4±13.0 (0–100)), test-related distress (mean 0.8+/2.2 (0–30)) and positive experiences (reverse-scored) (mean 3.4±4.5 (1–20)) scores were low, with no significant differences between Sydney and Melbourne participants. Post-education knowledge was good overall (mean 11.8/15 (±2.9)) and significantly higher in Melbourne than Sydney. Post-result knowledge was the same (mean 11.7 (±2.4) vs 11.2 (±2.4)). Participants with a B-JFM had higher post-result anxiety and test-related distress and lower positive experiences, than those without a B-JFM, but scores were within the normal range. Family cancer history did not significantly affect knowledge or anxiety, or pretest perception of B-JFM or cancer risks. Most participants (93%) were satisfied/very satisfied with the programme.Conclusion Both B-JFM screening programmes are highly acceptable to Australian Jewish communities. The programme enabled identification of several individuals who were previously unaware they have a B-JFM, many of whom would have been ineligible for current criteria-based testing in Australia.Data are available upon reasonable request. Data are made available in the supplemental materials. Further data are available upon reasonable request.